Q3 2016 13F Holders as of 9/30/2016
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
67.8M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
16.3M
-
Shares change
-
-1.07M
-
Total reported value, excl. options
-
$268M
-
Value change
-
-$17M
-
Number of buys
-
21
-
Number of sells
-
-17
-
Price
-
$16.45
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q3 2016
51 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2016.
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.3M shares
of 67.8M outstanding shares and own 24% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (5.38M shares), Novo A/S (3.22M shares), ADAMS STREET PARTNERS LLC (2.69M shares), FMR LLC (1.03M shares), PRICE T ROWE ASSOCIATES INC /MD/ (638K shares), JENNISON ASSOCIATES LLC (569K shares), BlackRock Advisors LLC (456K shares), Rock Springs Capital Management LP (450K shares), SPHERA FUNDS MANAGEMENT LTD. (325K shares), and venBio Select Advisor LLC (268K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.